Cover Image

Complete and durable remission of human epidermal growth factor receptor 2-positive metastatic urothelial carcinoma following third-line treatment with trastuzumab and gemcitabine

Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malig...

Full description

Saved in:
Bibliographic Details
Main Authors: Wezel, Felix (Author) , Erben, Philipp (Author) , Gaiser, Timo (Author) , Budjan, Johannes (Author) , Hardenberg, Jost von (Author) , Michel, Maurice Stephan (Author)
Format: Article (Journal)
Language:English
Published: January 2018
In: Urologia internationalis
Year: 2018, Volume: 100, Issue: 1, Pages: 122-125
ISSN:1423-0399
DOI:10.1159/000443280
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000443280
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/443280
Get full text
Author Notes:Felix Wezel, Philipp Erben, Timo Gaiser, Johannes Budjan, Jost von Hardenberg, Maurice Stephan Michel, Christian Bolenz
Description
Summary:Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malignancy. Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies. This case shows the potential significance of anti-HER2 therapy in selected patients with molecularly characterized UC. Clinical trials so far show inconclusive outcomes of anti-HER2 therapies in UC, indicating further need for both basic research and clinical studies for the identification of resistance factors and improved patient selection.
Item Description:Gesehen am 21.04.2020
Physical Description:Online Resource
ISSN:1423-0399
DOI:10.1159/000443280

Similar Items